Health Condition 1: O141- Severe pre-eclampsia
Conditions
Interventions
Intervention1: Levetiracetam: Loading dose: 1000 mg/day (500 mg twice daily) slowly over 5min intravenously.
The proposed regimen is to continue IV drugs for 24 hours then substitute oral levetirace
Sponsors
BLDE Deemed to be University
Eligibility
Inclusion criteria
Inclusion criteria: 1. All pregnant women with gestational age above 28 weeks presenting with features of severe pre eclampsia and imminent eclampsia during the period will be recruited into the study 2. Patients giving informed and written consent for investigations
Exclusion criteria
Exclusion criteria: 1. Patients who were diagnosed with other causes of convulsions in pregnancy like cerebral malaria and epilepsy 2. Chronic hypertensive pregnant females 3. Pregnant females with fetal anomalies detected on USG 4. Patients who withdraw the consent for further participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of Levetiracetam as an alternative to Magnesium sulphate in the prevention of convulsions in severe preeclampsia and imminent eclampsia. To evaluate the neonatal outcomes in babies exposed to levetiracetam and magnesium sulphate Timepoint: 1.Adverse effects st the time of administration 2. Occurence of seizures inspite of giving the drug 3. adverse effects of the drug at 24 hours 4 Adverse effects of drugs between 24 hours to 7 days after the administration 5. advesre effect of the drug at birth on the neonate 6. Adverse effect of the drug between 24 hours to 7 days after administration of the drug on the neonate | — |
Secondary
| Measure | Time frame |
|---|---|
| To study the perinatal outcoe after the exposure to the drugsTimepoint: adverse effect of the drug on the neonate at 1 month after the delivery | — |
Countries
India
Contacts
Public ContactDr Rajasri G Yaliwal
Shri B.M Patil Medical College, Hospital and Research Centre, BLDE(DU) Vijayapura
Outcome results
None listed